Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PASART-2
- 15 Jan 2025 Results (n=34) assessing long-term follow-up data from PASART-1 and PASART-2 studies and comparing these data during the same time period with the Netherlands Cancer Registry (IKNL), published in the Acta Oncologica
- 01 Dec 2021 According to results published in the Acta Oncologica, after an interim analysis, a protocol was amended to reduce dose of radiotherapy to 36 Gy in 18 fractions of once daily 2 Gy for 5 days a week to reduce the risk of acute post operative wound complications
- 01 Dec 2021 Primary endpoint of pathological near complete remission of the resected specimen which has been treated with radiotherapy has not been met, according to results published in the Acta Oncologica.